CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 31.35×, higher than 95% of its Biotechnology peers (median 5.71×)
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
285.35MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.58xvs all stocks
52-Week Change
-56.86%vs all stocks
Market Capitalization
285.35MUSDvs all stocks (USD)
Enterprise Value
-28.21MUSDvs all stocks (USD)
Forward P/E
-6.83xvs Biotechnology peers
Price to Book (MRQ)
0.9182xvs Biotechnology peers
Enterprise to EBITDA
0.3300xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-19.59%vs Biotechnology peers
Return on Equity (TTM)
-32.38%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
-56.10MUSDvs all stocks (USD)
EBITDA (TTM)
-85.40MUSDvs all stocks (USD)
Net Income (TTM)
-85.00MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-65.78MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-37.37MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-84.77MUSDvs all stocks (USD)
Pre-tax Income
-74.88MUSDFY2025 · Dec 31, 2025Net Income
-74.88MUSDFY2025 · Dec 31, 2025EBIT
-84.77MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-83.38MUSDFY2025 · Dec 31, 2025Research & Development
56.10MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
28.67MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-74.88MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-59.77MUSDFY2025 · Dec 31, 2025Free Cash Flow
-60.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
198.73MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-74.88MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.39MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.47MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.10MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
428.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.27MUSDFY2025 · Dec 31, 2025Capital Expenditures
-314.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-180.22MUSDFY2025 · Dec 31, 2025Sale of Investments
211.25MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
30.72MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
164.50MUSDFY2025 · Dec 31, 2025Shares Outstanding
76.29MSharesUpdated Sep 27, 2026Float Shares
63.49MSharesUpdated Sep 27, 2026Shares Short
7.19MSharesUpdated Sep 27, 2026Short Ratio
4.20daysvs all stocks
Short % of Shares Outstanding
9.53%vs all stocks
% Held by Insiders
3.35%vs all stocks
% Held by Institutions
103.51%vs all stocks
Total Cash (MRQ)
318.84MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.18USDUpdated Sep 27, 2026Total Debt (MRQ)
5.28MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0170xvs Biotechnology peers
Current Ratio (MRQ)
31.35xvs Biotechnology peers
Book Value per Share (MRQ)
4.07USDUpdated Sep 27, 2026Total Assets
366.28MUSDvs all stocks (USD)
Total Current Assets
357.48MUSDFY2025 · Dec 31, 2025Total Liabilities
17.28MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.80MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.24MUSDFY2025 · Dec 31, 2025Total Current Liabilities
13.05MUSDFY2025 · Dec 31, 2025Cash Equivalents
197.53MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
197.53MUSDFY2025 · Dec 31, 2025Other Short-term Investments
154.77MUSDFY2025 · Dec 31, 2025Accounts Payable
1.59MUSDFY2025 · Dec 31, 2025Short-term Debt
2.40MUSDFY2025 · Dec 31, 2025Other Current Liabilities
258.00KUSDFY2025 · Dec 31, 2025Long-term Debt
4.04MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
197.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
67.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-594.28MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
349.00MUSDvs all stocks (USD)
52-Week Low
2.83USDUpdated Sep 27, 202652-Week High
15.74USDUpdated Sep 27, 202652-Week Change
-56.86%vs all stocks
Beta
2.58xvs all stocks
50-Day MA
3.78USDUpdated Sep 27, 2026200-Day MA
6.85USDUpdated Sep 27, 2026Avg 10-Day Volume
1.50MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.67MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.21USDUpdated Sep 27, 2026Other Income / Expense
9.89MUSDFY2025 · Dec 31, 20255 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 31.35×, higher than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 31.35Industry median: 5.71Industry P95: 22.21Peers compared: 260
Price-to-book is 0.92×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.92Industry median: 2.86Industry P5: 0.98Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Santhera Pharmaceuticals Holding AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
Dirui Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inhibikase Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Perspective Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Abclon Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Inventage Lab Inc.
Tier 1ProductionApproval-Gated PipelineRule
Standard Biotools Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sichuan Gangtong Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Jiangnan Yifan Motor Co., Ltd.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Draganfly Inc.
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsDecline With Range Expansion And DrawdownLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Immuneering Corporation
4 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity